NervGen Pharma (NASDAQ:NGEN) Given Average Recommendation of “Moderate Buy” by Analysts

NervGen Pharma (NASDAQ:NGEN) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, one has given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $18.00.

NGEN has been the topic of several research reports. Weiss Ratings assumed coverage on NervGen Pharma in a report on Friday, April 24th. They set a “sell (d-)” rating on the stock. Zacks Research upgraded NervGen Pharma to a “hold” rating in a report on Wednesday, April 29th. Stifel Nicolaus raised NervGen Pharma to a “strong-buy” rating in a research report on Thursday, April 23rd. TD Cowen assumed coverage on NervGen Pharma in a research note on Thursday, June 11th. They set a “buy” rating on the stock. Finally, Wall Street Zen upgraded NervGen Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 29th.

NervGen Pharma Price Performance

Shares of NGEN stock opened at $2.12 on Monday. The company has a market cap of $170.94 million and a P/E ratio of -23.56. The stock has a 50-day moving average of $2.62. NervGen Pharma has a one year low of $1.70 and a one year high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02).

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.